ARTICLES BY YULIA PRIVOLNEV

  • Pharma Industry Braces For A No-Deal Brexit

    Chaos reigns supreme in London at the moment, as British Prime Minister Theresa May struggles to find a graceful way for the United Kingdom to exit from the European Union (EU). Meanwhile, pharmaceutical manufacturers must prepare for multiple potential outcomes, including a “no-deal” (or “hard”) Brexit.

  • The Brexit Deal And Its Impact On The Pharmaceutical Industry

    According to trade groups, approximately 45 million packs of medicines leave the U.K. for Europe every month, and 37 million go in the opposite direction. In a year, that’s almost 1 billion packs of medicines. What those borders would look like after a Brexit deal would significantly impact major industries in the U.K. and EU economies.

  • Brexit: The Good, The Bad, And The Chaos

    With just over half a year to go until the divorce date, and roughly two months until European Chief Brexit Negotiator Michel Barnier’s self-imposed October deadline for a Brexit deal, it has started to feel like we are finally seeing some concrete progress when it comes to Brexit.

  • Unpacking The Latest Brexit Developments And Their Potential Impact On Pharma

    As the divorce date approaches for the U.K. and the EU, one would be forgiven for thinking there would be a plan in place to deal with an event that will have such a profound global impact on the pharma industry. However, manufacturers have to prepare for any possibly scenario, while continuing to wait for clarity.

  • Should Pharma Companies Even Care About Brexit?

    It is difficult to assess the ultimate impact of Brexit on the pharmaceutical industry when so much remains unknown. However, many would argue it is exactly this uncertainty that makes Brexit so disruptive. 

  • Preparing For Brexit: Advice From The EMA

    The U.K.’s Business, Energy and Industrial Strategy (BEIS) parliamentary committee announced it is investigating the implications of Brexit for the U.K.’s pharmaceutical market, amidst fears Brexit will threaten "the cost of medicines, investment in the United Kingdom and access to new and innovative research and products."

     

  • What Is Pharmaceutical Innovation, Anyway? Italy’s New Algorithm & The Global Trend

    Innovation has long been a topic of focus in the pharmaceutical industry, with developers striving for it, regulators and payers demanding it. But, what exactly do we mean when we talk about “innovation”?

  • Brexit & The Biopharma Industry: 3 Important Developments To Watch

    There have been considerable updates in the Brexit situation since April 2017, including, the surprising result of the U.K. general election. If anything, news regarding Brexit and the biopharma industry has started to heat up in recent months, and there have been a number of relevant developments that manufacturers must keep their eye on.

  • Brexit & The Biopharma Industry: What Happens Next?

    For all the talk of “hard Brexit” and “soft Brexit” and discussion surrounding the post-Brexit relationship between the U.K. and EU, we still don't know much more than we did a year ago. 

  • Brexit’s Impact On The Global Pharmaceutical Industry: Market Authorization & Pricing

    The Brexit referendum has resulted in instability and uncertainty for many aspects of British society, including the pharmaceutical industry. As we discussed in Part 1 of this two-part article, life sciences funding and the common market are at risk, and with it billions of dollars in research funding and imports/exports. In this article, we will explore the UK’s future relationship with the EU after exit, which will affect many facets of the worldwide pharmaceutical industry, from marketing authorization to global pricing trends.

  • Brexit’s Impact On The Global Pharmaceutical Industry: Future Access To The EU Common Market

    On June 23, 2016, the voters of the United Kingdom voted to leave the European Union in an advisory referendum colloquially referred to as the “Brexit” (British exit) vote. The aftermath of the vote has been chaotic — from financial troubles that have seen the British economy and currency plummet, to political bedlam that has led to a number of political casualties, including the Prime Minister and his heir apparent. While analysts, journalists, and the public all discuss the impact of Brexit on the UK and the path forward, few realize the implications that the vote will have on healthcare, and the pharmaceutical industry in particular.

DRG-Yuli-Privolnev

Yulia Privolnev

Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group (DRG). She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement (A&R) products. Privolnev's specific focus is on all aspects of market access in Western and Eastern Europe, as well as international reference pricing (IRP) and managed entry agreements (MEAs) on a global scale. She earned her M.A. from the London School of Economics.